Replay available

Ypsomed Holding (SIX Swiss: YPSN) Q2 2027 Earnings Call

Ypsomed Holding (SIX Swiss: YPSN) reported Q2 2027 results on this call. Replay available.

Wed, November 11, 2026 at 7:00 AMendedReplay
Ypsomed Holding (SIX Swiss: YPSN) Q2 2027 Earnings Call
Company
Ypsomed Holding AG (SIX:YPSN)
Period
Q2 2027 earnings call
Date
Wed, Nov 11, 2026, 7:00 AM ET
Replay
Watch the replay on this page · 1 h 6 min

On 6ix: 6ix.com/event/ypsomed-holding-ag-0qlql-q2-2027-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Good morning, good afternoon. Welcome to all. Thank you for joining us today for Ipsomed half year results 2026-2027. With me here today, our CEO Simon Michel and our CFO Samuel Künzli. Simon will start and go over key achievements for the half year for the last six months, followed by Samuel who will go over a financial performance. After a prepared remarks, we will open the line for questions. At that time, please click on the hand raise icon and unmute your mic.

0:43 thank you very much for joining us and without further ado i'll hand over to simon please thanks a lot sam for introduction thanks samuel for joining me here on stage uh let us start right away and uh move into the slide deck we have prepared a small slide deck i'm sure you have I have seen the news, we had a great first half of the year, very pleased with the achievements of the team and especially exciting I think the first time in my 14 years as a CEO here at Ipsomed, we are raising the bar, we are raising the guidance for the full year. Ipsomed, we get up every morning because we make self-care simpler and easier. We help people with chronic conditions and that's in the core of what we are doing. And we benefit from those structural growth drivers.

1:37 More care goes home because it makes sense. It's better for the quality of life and it lowers health care costs. We profit from this explosion of biologics of large molecules. Only very few molecules can actually end up in a pill. Most of them end up in a device. That's where we play. Biosimilars, the golden age of biosimilars. That's where we play as well. We don't only work with originators. We work as well as with biosimilar companies all over the world. We are going to deepen that today. And the incretins, the GLP-1s, you know, we are now at close to 50 clients in that space. Very broad, interesting new area where we can play an important role.

2:23 We are through with our transformation. We are now a pure play self-injection specialist. That's in the core, in the heart. And now you see the pure IPSOMED as we stand and as we grow. We have divested everything which doesn't fit to us. Let us today deepen in four distinct areas. I'm going to do with you the platforms innovation and operational excellence, some updates. and then Samuel will join me here back on stage and go with you through the finance before we open for Q&A. On the platforms, it's always very important to mention we have by far the broadest range of self-injection solutions. And I think that's especially important to know that we are the only company to actually switch clients from auto-injectors to pens or from pen back to auto-injectors.

3:14 We have this broad opportunity to offer everything our clients may need. We have three new products now, that's the IPSO Dot, IPSO Flow and IPSO Loop, so two pen devices and one new autoinjector. When we look at all revenue, then we are above 70% now coming out of autoinjectors and roughly a third in the space of pens. This may now change again, we will see how it develops, but at the moment our clearly strong, strong growth driver is the autoinjectors. And we have been super successful over the past six months. We have won 30 new deals, 30 new projects, and that's over two thirds of what we have done in the past full year.

4:02 And it's remarkable that it's in a very broad spectrum. Only a very few of those actually come in the GLP-1 space. That's the blue bar. at the majority comes out of a very broad range of autoimmune diseases that we support in the space of neuro drugs etc and they come from both developed and emerging markets and we have one 10 new customers so we are now at 130 customers we will deepen that in a minute Where we are particularly proud of is the fact that four out of five device launches over the past 12 months in developed markets come in an IPSA mate. And that shows the strength and the standing of our company. This is the leading company in that space.

4:53 And we see it now more and more over the next months and years, what we launch. A very broad spectrum of devices. and also broad in the sense of therapeutic areas. With 130 clients, we are now active in close to 300 clinical and commercial programs. Ultimoon is the leading and fastest growing space, followed by incretins and diabetes, but with more and more hormone therapies, rare disease stuff, etc. Out of these 280, roughly 90 are actually launched products. So we have 90 in the market and 190 currently in development and kind of every year 50 ish adding to the project portfolio. And it's a very broad scope.

5:45 Again, you are aware of it for both pens and auto injectors. So those deals, those products are very broad spread over 130 clients. and the biggest 10 clients they make roughly 50 percent so we don't have this topic anymore as we had it 15 years ago with one very strong client even NOVO is very important but is far away from 15 percent so NOVO is an important client and will be an important client but we are not dependent on the development of the company Let me move into innovation. I think it's important to mention that we are very active in the field.

6:33 We lead the main conferences at CPHI, at the PDA in the US, we are on the main speaker list, we are in very close contact with Big Pharma, we understand where they want to move tomorrow and based on that we also adapt our innovation and platform portfolio. One new element that struck over the past two years is time to market, time to clinic. That's where we can support our pharma partners. We have to shorten the time in phase two clinical studies. We support them doing studies at home, making it more comfortable for patients. and in the end skipping the relevant bridging studies and that saves time when we are already in 2B into 3 and then into market in the same device and that's a game changer and that's only possible because we collaborate very closely with the different glass manufacturers so concretely what does it mean we are pre-verifying pre-validating the combined product So we work with the glass and the rubber manufacturers, we take our device and we make thousands of tests and we deliver to our clients the finished documentation.

7:49 By that they can gain a lot of time, they can go much faster into the clinical trials and then eventually into the market. we are now we are now way below six months our target is to go down to three months my vision is to be off the shelf you can really call us and you get devices to go into a study because it's standard it's prepared there's a lot of work behind it but it's extremely relevant and because we are so well networked in the whole organism in the whole industry we have set up those offerings Apart from those innovations in the space of products and services, we are investing a lot of money in AI. AI is not only the actual brain power, the actual computational power, it's also data.

8:38 We have spent a lot of time to aggregate data over the past months. We have now databases that support us being faster in manufacturing and being more precise in manufacturing. We have now less and less waste, we are raising the OEEs, so the productivity of our lines, and we are prolonging the maintenance windows. So we have less maintenance, we only take care of our lines once they really have an issue, so we use the sensor data and the brain understands it, sees patterns and tells us when we have to do the maintenance. Our vision is to eventually get rid of in-process control because the process is so stable that we no longer need those analytical special tests, which take time and cost money.

9:29 Let me now move to the last topic here, the operational excellence. Operational excellence at IPSAMED is mainly broadening our footprint getting the capacity ready that we see in the coming years so we are now when we look at the portfolio of sites now really nicely spread we have our Swiss and German sites for Europe and some of Eurasia we have Changzhou for China and we have our new site in Holly Springs In Solothurn, now since we have no longer contract manufacturing here, we have enough space to upgrade it, and we are currently implementing state-of-the-art automation. We have those automated self-driving cars.

10:15 They support us in logistics, make us much more efficient. We are building a new fully automated warehouse, which is required because of the massive volumes of auto injection that we want to bring out here in Switzerland. At the same time, in China, It just works. I mean, we don't even have this as a topic on board level. It just works. We have now space for one more line. We bought the land on the left. You see here on the picture that we can grow if we decide to grow. But I'm very, very pleased with the work of the team here in China. We deliver both locally but also into some neighboring markets and this will also be the case in the future. Changzhou is on the same state of the art level as our other sites.

11:02 You see here the angle lines that you know nicely set up, highly automated as well. Let's move to Germany. That's a picture from last week. We are getting ready here to ramp up the manufacturing, which is next to the big cube. It's almost ready. We are at the moment bringing the first lines and the first 20 or 30 plastic molding machines in. The huge cube that you see has space for 25,000 pallets. It is made for over half a billion of all the injectors and pens. This site that you see here has the capacity of roughly 250 million, so we have space to add one more unit in 2029-2030. In the front here, you see the building that we require for office space, for projects, for customer meetings, etc. This will be ready roughly in June.

11:53 We will open in summer officially, but the manufacturing is handed over as we speak. We have to ramp up because the original building to the right is full and we need to ramp up the new clients. America Now, we brought up the sign last week in Holly Springs. Very pleased. The building is now being refurbished respectively. We are now doing the work on the flooring and on the technical and then we will be able to hand it over to manufacturing in September 2027. And this is also when the first lines will get in. We see at the moment the realistic delivery of first products out of Holly Springs in Q1 2028. With that, ladies and gentlemen, I would like to hand over to Samuel.

12:42 Samuel will deepen with you our figures, he will deepen with you our performance and explain in a bit more depth our outlook. Samuel, please.

12:53 Thank you, Simon, and welcome from my side. In the around next 10 minutes, I will give Let's start with our top line. We achieved 318 million Swiss Francs of sales. You see here on the left side, the majority is coming from our main business. The delivery system business is the business with the own pens and auto injectors. 31 million Swiss francs is coming from other business areas this is for now mainly the two contract manufacturing we still have going on the one for the pens just ending those days and the other the contract manufacturing for diabetes care so insulin pump consumables that one's still going on until end to end of the decade Let us now have a closer look at our main business.

13:58 The delivery system business grew 17.5% in the first half year. What you see here on the left side is that commercial sales, they grew very strong from roughly 200 million to 243 million, so more than 20% growth. that was driven mainly by our auto injector platforms by the the high runners the Ypsomate 1 ml and also the 2.25 ml The project revenue grew from 43 to 44 million. Project revenue for us is the customization we do of our platforms for customers and the clinical samples we deliver for the clinical studies.

14:51 Those of you who follow us longer, they know that the project revenue doesn't have the same dynamic as the commercial sales. The main reason there is also our customers they use our platforms as platforms so many of our new projects are repeating customers so there we have less customization fees and also the clinical devices we deliver for clinical studies by nature that is a more volatile business. Let us look now at the profitability. We achieved 102 million Swiss Francs of EBIT, that's representing an EBIT margin of 35.7%. So similar like in the last business year, an EBIT margin close to 36%.

15:45 in the others we had a minor loss of three million swiss francs that is mainly coming from the and carve out the phase-out of the remaining contract manufacturing for the pen business and is partially compensated by the profit we do with the contract manufacturing for the diabetes care business. We reported around 100 million Swiss francs of EBIT in the first half year. Let us now have a look at the cash flow. operating cash flow was strong close to 120 million swiss francs what you see here that the cash flow from from investing activities was still slightly bigger than the operating cash flow so we ended up in a slightly negative free cash flow but you see we are already close to being free cash flow positive The cash flow from investing activities we will now have a look at it that was mainly growth investments and investments in innovation.

17:00 We see that on this slide. We invested 130 million Swiss Francs in fixed assets. Simon showed you the buildings in Switzerland, in Germany, China and US. You saw the plastic molding lines, you saw the intralogistics. That's where our fixed assets investments go to. The innovation investment, these are these investments in intangible assets, that is the next PEN platforms, so the platforms like Ypsoflow and also the next auto-injector platforms, the YpsoLoop, they are in those investments as well as the digital health investments.

17:46 If we look at our capex investment cycle, we see that we are now in the business year 26-27 close to the peak like in the last business year 25-26 we also expect this year fixed assets investments being close to 300 million swiss francs before we gradually go down with those fixed asset investments and you see we expect already in the business year 27-28 to be on free cash flow level positive but it's also important to note our investments they are in this in the production manufacturing these are all flexible and modular investments and we reach although we are in this ramp up and peak investment phase we reached a very high capital efficiency also in the In this business year, in the first half year, we reached around 20% ROSI, so around 20% return on capital employed.

19:00 Now, how do we finance those investments? You saw before the operating cash flow being already north of 100 million. What you see here now is the EBITDA of the last 12 months was already north of 300 million Swiss francs. Now current debt level is on around 300 million. That gives us a net debt to EBITDA ratio of around 1.0. this is a very solid balance sheet and this balance sheet allows us to finance this growth capex cycle and also allows us to finance our growth strategy now finally looking forward simon mentioned it it's a special day so we raise our guidance the initial outlook for this business year was a top line growth of 12 to 15 percent on sales and now we raised that to 13 to 16 percent and the same on the profitability level we initially guided 210 to 230 million swiss francs now we lift that to 220 to 240 million swiss francs Before we come to the Q&A, I show you the mid-term outlook.

20:32 Also here we confirm our mid-term ambition, which is to reach on the top line 0.9 to 1.1 billion Swiss francs of sales and to reach on EBIT level 280 to 340 million Swiss francs until the business year 2930. The capital efficiency should stay around this 20%. And what is especially now favorable for us, we also see now coming closer to that end of the decade, we see that growth also after 2030 is persistent and we see a sustained growth also in the years after.

21:17 With that, I would hand over to Sam to lead us through the Q&A. Thank you, Samuel. Thank you, Simon. A remarkable year indeed. Many firsts. We'll now open the line for questions. Thank you. We see already a few of you already clicked on the hand raised icon. We'll go in order. So we'll start with you, Daniel. Would you like to unmute your mic and ask your question, please? Hello. Just checking we would need. Hello. Perfect. We're hearing you. Thank you very much.

22:02 You see me?

22:05 We hear you, Daniel. Good afternoon. That's great. And we see you. Good afternoon. How are you? Good afternoon. Excellent. And with these numbers, could be better. So thank you very much for the good print today for you, Simon and Samuel, and also to the IR team, by the way, which did a great job over the last few months. So my question is the first effect of the Solothurn phase out with Sanofi where you produced I think two months now in the second half October November and then you have probably the transfer the renovation the maintenance so is that probably baked into the full year guidance which is implying a bit slower I mean second half growth still very good of course but is that you hear you well okay yeah that was it's good okay now it's better sorry yeah you got the question maybe I just asked the first one out of the three

23:25 great why don't you want to start absolutely thank you daniel for the question so you're absolutely right so we we said sanofi the contract manufacturing will only have a minimum impact on second year sales because yeah we said october november it will stop so for you fair to assume there is minor sales on that we said also there will be a minor impact on the bottom line but this is shown in the other segment so not in the delivery system and this is also not included in our guidance the guidance is for our main business the delivery systems this other business which had in the first half year now a slightly negative EBIT for you it's fair to assume also in the second half year yes we will have a slight negative impact of the Sanofi phasing out and this is partially compensated by the contract manufacturing profit we do with the diabetes care products but think of it as a low single digit negative impact we will see in others in the second half year feel free to add Simon if

24:43 I think we are very well on track. This is all foreseen. It will take us roughly half a year until we run the lines up. We are installing, as we speak, plastic molding for both NOAH and many other clients. We have a flexible system installed. It's a platform approach as well, so we can really proactively use these volumes. Yeah, thank you. And just maybe one more question. That's OK. I was really astonished by the high margin you can keep despite the ramp ups in all the locations. I mean, how is that possible? I mean, I'm really astonished by that.

25:30 I could start and feel free. So I tried a little bit to highlight that. So the product mix was really favorable for us. For you, it's fair to assume that the auto injector business has a slightly higher margin than the PEN business. And we tried to explain that the growth was driven by the auto injector business. So by the one milliliter platform and the 2.25 milliliter platform. And that was really the main driver for this good margin, which we could achieve in this first half year.

26:08 and then it's also the case that it doesn't necessarily mean that in biosimilar we can only charge lower prices obviously there are clients where we have to go lower but we have also clients in China that pay European American prices so we always try to understand our clients We spend a lot of time in pricing. Pricing is an art, became an art. We have an excellent sales team. They understand the respective geographies, the respective clients. We do a lot of base work. We have done a review a couple of months ago and we have asked all our clients how they perceive us. the majority perceive us as not the cheapest one as though we actually perceived as the most expensive one in the industry but 99% I think it was one out of 85 clients said they are too expensive so the majority of clients say yes we pay a lot of money but we know what we get and this is our promise you know we have to deliver and this has a value and we try to optimize it for both sides Thank you very much.

27:38 Thank you, Daniel, also for your question. And now we'll go to Sybil from Fontobel. Would you like to unmute your mic and ask your question, please? Thank you very much for taking me and congratulations on the numbers. I also was pleased as Daniel. The first question is about the other EBITs, so this minus 3 million. Could you tell us how pump divestment, pump contract manufacturing, pen needles and so on was helping this minus 3 million. That's my first question.

28:21 I start with that one, hello Sibyl. So we had two elements which had a slightly negative impact that was on the one side the contract manufacturing of Sanofi because yes volumes were already lower so this phasing out that had a slightly negative impact and also really the last last pen needle transactions in there that was negative and a little bit helped was the contract manufacturing of the diabetes care products so the infusion sets and the reservoirs but you saw it could not fully match so we had still net around three three million negative EBIT that was is the story around this other result so no no other negative EBIT from the pen needles so this this is done now yes good and then the second question is about the midterm outlook which you confirmed about sales 0.9 to 1.1 billion swiss franc are you still sticking to the lower end of the outlook or is this now open so the whole range to be expected we haven't really discussed that one

29:42 We are definitely hitting this landing zone nicely, but let us get back on that one. We don't make a new statement on the mid-term outlook, but when we see what we have delivered now and for the full year and also 2027-2028, which looks better than we have expected half a year ago, we are very confident that we are going to land in the landing zone that we provided to you. Absolutely.

30:09 For you it's fair to assume since we raised the guidance that the situation at least did not get worse. Sounds good. And the last question is about capacity reservation. In commercial could you help us with how much you could book in the first half?

30:32 Yes, I started that class. I maybe start with the overarching picture. We have a business model which is reliant also on co-financing. The rough indication we gave is of our 1.3 billion capex plans, so think of it as roughly 30% is co-financed by capacity reservation. What you see in our balance sheet on the liability side, Sibyl, is always what is still left in the balance sheet. So that is slightly more than this 200 million. But you need to have now in mind that part of it is always recycled.

31:21 the math you can do there is you look what is recycled annually so that's around 20 to 30 million which goes out this is the short term part and when the example if overall it stayed constant for a year 200 then it means roughly 20 came in addition so that gives you a rough idea how this works and also how you can read it but happy also to deep dive with if there is questions on that I'm fine. Thank you very much. Thank you to you too, Sibyl. And now we'll go over to Tania from UBS. Please feel free to unmute your mic and ask your question. Hi, good morning and thanks for taking my questions and congrats as well on the great result. I have three questions if I can.

32:15 I'll go one by one. you upgraded your guidance this year so how should we think about the cadence of growth going into the next years as the new contracts ramp in terms of the midterm guidance will it be even phasing or back-end loaded that's the first question so we try to be quite evenly phased we of course we cannot

32:39 I guarantee you a straight line. There might be some bumps, but no real bumps. I mean, we definitely don't see any more of this knick, this slowing down in 2027-2028. We have a lot of new contracts that will deliver in 2027-2028. The year looks already much better than we expected half a year ago. So we are really positive that we can provide to you the 15% CAGR. and it will not be a straight line, but it will definitely be much smoother than we expected half a year ago. Great, thank you. That's very helpful. And then second question on the EBIT margin. What level of margin pressure do you expect each year until 2930? Will it be a gradual fade down or some volatility as new capacities ramp up next year and weigh on the margins?

33:35 So frankly speaking, all we have guided is above 30%. It doesn't mean we need to reach 30%. It may also mean we are way above 30%. so at the moment we see a couple of larger deals where we get less per device that will actually start ordering in 28 29 that will have a more effect i i would say in the coming 18 months 24 months even we will see a short some decline that's mainly due to some biosimilar markets in china mainly but then the larger volume deals they kick in rather at the end of the decade I don't believe we will actually hit the 30%, but it will not be straight.

34:28 We should probably try to deepen that a bit more for the full year. Do you have anything to add here, Samuel?

34:34 Well summarized. I just also want to remind you and those of you who follow us close know that we have a volume-based pricing. So although we have this REMPAC more capacity being online utilized we give that economy economies of scale also to our customers that's why it's fair to assume that EBIT margin slightly goes down we had a very good EBIT margin now but as Simon said we we are comfortable to stay above the above the 30 percent so that's my five cent on that one great that's very clear and then the last question if you could provide an update on you know what part of your pipeline is GLP and where do you see GLP sales in percentage going towards by the end of the decade?

35:28 So we have given you an indication one year ago that was roughly in the space of 10% where GLP-1 is at the moment. We also have told you that we may reach one-third by end of the decade. You can assume that we are somewhere on that way, underway from 10% to 30%. We have at the moment close to 50-5-0 GLP-1 deals, incretines, both in open check and some In PENS, we have relationships such as Innovant with Mats to Diet that explode, that just order, that actually move the therapy away from clinics into beauty saloons. So a new business model in China, B2C, out of pocket.

36:20 So it's pretty difficult for us to judge, but I would say we are now above 10%, but way, way, way below a third. Thank you. And maybe, if I may, have a closer look at our autoimmune pipeline. You know, we are very broadly set up, and these companies pay pay really good money for our devices because they have so expensive molecules, they want to get the best. And also, not just the one ml, we move more and more into larger volume devices. We move into 2.5, move into 5.5, and this is expensive stuff. So this actually increases our margin, and when you look into the space and also the graphs where we have shown you that only a small portion of new deals is incretins, you can assume that you're actually increasing the interesting deals outside of incretins as we speak.

37:30 Thank you Simon for providing the additional colour. I hope that was helpful, Tanja. And now we'll move to John, John from Barclays. Please unmute your mic and ask your question.

37:42 Hi, good afternoon. Thank you for taking my questions. John Nunn here from Barclays. I actually also have three. The first one is just to follow up on the FY28 margin. It seems like the margin this year is going to be better than you'd expected. Closer to 36% in the first half and the gap between 36% and 30% is quite big. So I wonder if you could help us think about where in that gap you might finish for FY28 on the margin. Is 33% the right number? 31? Just some context to help us try and frame the model for next year, please.

38:19 So for the current business year or for the next business year?

38:22 For FY28 please.

38:26 Yeah, we come with the official guidance in May next, in May 27. I tried to give a little bit color on that. Of course, we are now ramping up, so that is for sure giving somehow us a headwind. On the other side, yes, we have economies of scale, which we realize, but we share them with the volume-based pricing. We have bigger contracts ramping up. But it's not that you should think of a huge fall of the margin, but we said we somehow gradually come a little bit down with the margin. But a precise number, a precise guidance, we come up in May 27 for the 27-28. Fair enough.

39:15 I'll have to try.

39:20 And then my second question is on the Ipsifit program and the potential benefits you could see from improving the utilization and also some of the procurement programs that you've spoken about, like dual sourcing of plastic. When could we see some benefit to the EBIT line from these programs? And could you help us to think about the magnitude that these programs could bring on EBIT?

39:45 So the program has actually gotten much bigger than we originally expected. So we are kind of turning every stone in the space of dual sourcing and new plastic. We also move for many clients from medical grade to food grade, which is a much cheaper sourcing because you have less paperwork and customers are very happy. We will see the first effect in 2028. You have to assume that these are product changes together with the clients and the clients have to The clients have to reapply in some countries because of the new material. Most clients will be part of it. We are obviously sharing the cost reduction with our clients in order to motivate them, but you will not see benefits in 2027.

40:30 It will soften the EBIT effect in 2028-2029.

40:39 Okay, and just to confirm on that point, in the midterm EBIT guidance, are you assuming a significant benefit from utilization procurement improvements in that reconfirmed guidance or could it present upside to FY30 EBIT guidance?

40:54 So, yes, so that's the reason is, you know, we will not see the 30. We'll be clearly above 30%. We cannot guide at the moment. And IPSA Fit will definitely have an impact on that. Definitely have an impact. we have to move all clients by 29 to the new material that's that's the order I have given inside it's very clear very clear task we have we have to move we have to simplify we have to have dual sourcing and we also motivate our client to do so yes we will see an effect in in the outlook okay and my third question is on M&A you've spoken about

41:30 potential for M&A and firepower for M&A. I just wondered if you'd give us some idea of what kind of things you would be looking at, adjacencies or market expansion and potentially any timelines you had in mind.

41:44 So when we look at the potential and organic growth at Ipsomet, we differentiate between horizontal and vertical. Horizontal means we are trying to add new platforms that we have not in our own innovation pipeline. And at the moment we look at two options. We have two potential adding that would fit nicely into our family. We are analyzing them, we are talking to them, we are not negotiating yet, but we are in the phase of deciding which of the two will have a first priority. Number one. Number two is the vertical. We try to understand much better the roles of the different players in the vertical.

42:30 Not just the device, but also the glass, the fill finish, and of course the assembly and packaging. So in the vertical, our vision is clear. As an industry, we must simplify the supply chain towards pharma. There are not so many targets out there, frankly speaking. In each of those spaces, you have one to three companies. We talk to them. We have intense discussion, but we have not negotiations yet. We are trying to give you more flavor on it and also on the prioritization at the dedicated market day in 27 where we want to explain you the benefits of moving into such a space because you have been asking now a couple of questions on our bottom line and obviously we don't want to jeopardize our group bottom line too much with those new elements in our family. So we want to give you much more flavor in summerish on that topic. But I can tell you we have a good team, a great team.

43:26 We have support of consultants in the two areas, vertical and horizontal. Great, thank you very much. Thank you also, John, for your questions and interest. We now go to Sandra from Octavian. Please unmute your mic and feel free to ask your question. Yes, can you hear me? Good afternoon. Also from my side. I have first a little bit more strategic question on China where you're ramping up the capacity and you have said China should become a meaningful part of your production footprint in overtime. Now, how do you see the competitive environment in China?

44:12 Is it particularly on pricing also competition from potentially local device manufacturer and do you think you can with your existing platform can you compete in the broader Chinese market or would you also consider kind of a dedicated low-cost offering just for this market and if is that a topic for the M&A or would that rather be developed in-house?

44:45 Great questions. First of all, when we look at the manufacturing capacity we are going to have in China by the end of the decade, out of the one billion capacity by 3031, we will have roughly 150 million, 120-150 million in China. So yes, it's important, but I would say Germany makes 50% will be much more important. Number one. Number two, we have to differentiate in the segmentation of the client's five segments. So we look at premium, premium plus. That's mainly global big pharma. Then we look at hybrid, that's this GLP-1 incretin space. And then we have Value Plus and Value. Value Plus is local companies in emerging markets that attempt to sell outside of the domestic market, i.e. a Chinese company tries to sell larger in the US.

45:43 And then you have the Value Market, which is the actual domestic local market. where we want to champion and where we are currently championing is in every segment above value value plus we are the one that is selected every chinese company who who wants to sell outside of mainland china is selecting ipsumit so that is that is given and that we can do with our current portfolio where we have to look at and that's why we have a close look at china mainland china is the value segments What we will not do, we will not take our existing Unopen and existing Ipsomate and cut the price by half just to get some domestic volume. We will not do that. For sure not. We have three passes at the moment.

46:29 One is our new Neopen low-cost platform, which is under development. One is a program with a Chinese contract manufacturer. And then thirdly, we're actually also looking at acquiring a local Chinese manufacturer. We have done the analysis. We have looked at a very broad space of Chinese pen manufacturers, roughly 30. Out of them, four or five really do a good job domestically, still a small volume, but they can deliver quality. We are definitely not looking at companies with backyard job level style. So we look at serious medtech companies and we have a clear understanding who is there, but we haven't started, as I mentioned just a minute ago, we haven't started yet any negotiations.

47:17 We are in the learning phase, the education phase, but those three options are actually relevant for us to win in the value segment. all other segments our portfolio we are well set up thank you very much appreciated for this for all these details thank you and then if I may a second one sorry I know we already talked a lot about the margin but I have to follow up here again only for the second half so the guidance implies that second half margin will be kind of lower than the strong margin in the in the first half. So for this year, is the main driver for that already greater ramp up costs or is it mix? You mentioned biosimilar launches or what is it just for the next six months?

48:04 What is driving or is it just a cautious guidance? What is driving down the margin otherwise?

48:11 I start and then feel free to add yeah it's it's on the one side for sure ramp up which is which is going on so that that costs we we have product mix to a certain extent as well you can somehow read that yes auto injectors now became very good but on the other side yeah the pen business is also running well so so you see the product mix plays a role in that as well and that That together gives you that when you just look half year by half year, this slightly lower profitability in the second half year. Okay, thank you. Thank you too, Sandra, for the great question and interest.

48:57 We'll now move to Anna, please, Anna from KeyBank. Feel free to unmute your mic and ask your question. Hi, good morning. Thanks for taking my questions. Maybe first to start on your long-term guidance to 2030. I think when you first gave that guidance, you assumed flat project growth. But I think in this half year, you saw another record project orders. So is there any area of upside in the guide around the project side? And does the record number of orders suggest you're gaining share here in the

49:37 So Anna you know I mean we have defined our landing field our landing zone quite broad you know 0.9 to 1.1 and this obviously includes the potential of stronger growth and so we can just reconfirm that we are comfortably landing going to land in that zone but we are not adjusting our guidance as we speak for midterm we'll definitely have a close look at it for may at the moment we are highly confident to reach it and of course the new projects because your question is really relevant i mean when we sign a deal today it takes two to five years until the product launches and um and and obviously some of those new deals are going to launch in in in that in that time so it has an effect on the on the actual landing um great thank you that's very helpful and then another um topic maybe just the larger volume biologics i think you mentioned that that was a growth driver um is this mainly in the funnel today or are you seeing these in commercial just trying to get a sense of where we are in this industry shift. And I think you also mentioned these are some of your highest margin products.

50:57 So is there any way you could quantify maybe margins of your high volume auto injector versus some of your lower volume auto injectors?

51:09 So that's really picking up, but I'm not aware of the... Are we allowed to say names? Sorry, can you give us names here? Just broadly, I think the space, I think it's quite interesting. Maybe we can give you a bit of color. Yes, autoimmune therapies that are already launched are growing and we're benefiting from this. And also we're winning a lot of new clinical projects.

51:28 But do we have a product in the market that we can name? We have a partnership with Medac that we also already disclosed. And we also have some exciting products in the market, for example, for Alzheimer's disease that also is well known on the market.

51:46 In the 2.25, interesting, in the 5.5? and yes those would be launching soon okay so i think we will have in q127 we will have the first launch in 5.5 so to answer your question we are i'm just in the in the mode of going going a commercial on the volumes but we have we see a very strong inflow when we are at the conferences there's enormous interest pharma companies realized that their molecules have a much higher viscosity and they are actually requiring larger volume. So we see a strong rise. This will have a positive impact in the mid-term on our bottom line.

52:27 And if I may add to that one, what we mentioned now already, that the 2.25 ML platform that that was one of the main growth drivers. So for you, it's fair to assume if we say they grow faster, that this growth is already above the 17 and a half percent, which is the average growth. So that gives you an idea about that large volume segment and the growth dynamics there. Thank you. And maybe just my last one is overall on auto injectors, can you quantify what that grew in the half year.

53:09 Yeah, we understand the question, but we don't declare a pure auto-injector growth rate. But what you can derive from us saying 1 ml and 2.25 ml is growing faster, that auto-injector growth was more. than the 17.5% and pens therefore was less. So you see there is a different dynamic but I also want to highlight we feel in pens and I mentioned it before a little bit when we talked about product mix we feel also traction in our pen business especially now also in the GLP-1 and in creatine space.

53:46 We have dedicated solution in the space of GLP-1 with the IPSO DOT and IPSO FLOW. I think these are great devices that are actually built for GLP-1s, where we can achieve interesting margins because it's unique features that we don't see in the autoinjector. But at the moment, as I mentioned, we are above 70% now on all the injectors. It may increase a bit, but we also see somehow in this area until the end of the decade because there will be a revival of PENS to a certain extent. Thank you and congrats on the results. Thank you too Anna. Thank you. We'll now move to Urs from Research Partners.

54:32 Please feel free to unmute your mic and ask your question Urs. Yes, hello Simon, Massa, Amel and Sam. Congrats on the great achievements in delivery systems. Maybe first just a thing to clarify you in delivery systems. You said you saw growth also in the PEN business in first half

54:56 26-27. Yeah, so we said PENs grew less than the overall growth. So that's for you to assume pens grew less than the 17.5% and auto injectors grew more. We don't declare here the specific growth rate of those areas. Yeah, that's fair. Then my other questions are around the others. Maybe first to the contract manufacturing to my life group. That was 20.7 million in the first half of this year. remember numbers like 50 millions a year so why is that low to or is it now lower than than the close to 50 millions and then you said on that thing that you will do that till the end of the decade so a little bit longer than than you assumed before is that correct

56:01 So I'm taking the second one, maybe you can take the first one.

56:03 Yes, so it's right that we said roughly 50 million per year, but you read correctly from the numbers. If only 31 was from others and there was still the contract manufacturing from the pen in it, you can assume that yes, it was only a little more than 20 million. And so for you, yes the top line we will we don't expect from this contract manufacturing for my life we don't expect now fully 50 million this year so rather think of it something between 40 and 50 million And about the duration, I hand over to you, Simon.

56:42 I think this volume also shows that we, together with MyLife Diabetes Care, we support also their transition. They have also selected the contract manufacturer outside of Ipsumet that is going to ramp up in 2027-2028 the first line. for us it's important that we have a smooth transition you know we don't want to stop immediately so we may see the peak of 50 million in the end of 27 28 we may not but then it will definitely go down and our interest is that we have a smooth decline then over the over the course of two to three years until latest latest 2030 because we need the room we need the space for ipsodose and other products. This is nicely managed. We have a good relationship with the team over there and we just try to reduce in order to keep the people, to use them for our, to retrain them on our autoinjector lines in Schwerin 2.

57:37 And if I may add, I didn't want to give the impression that we now prolonged that. I wanted to say it was rather by end of the decade that will be phased out.

57:45 We have clearly an interest to move it out. It is important now. It's an important job we need to do. At the moment, they are almost our biggest client. You shouldn't forget. Obviously not from a bottom line perspective, but we want to do it professionally and as smooth as possible. on the EBIT this minus 2.5 million new said we have to expect about the same minus in the second half and in this first half of the minus 2.5 million was there any impact on from the needle business regarding this earn out of two millions that you still have in your balance sheet this is that still there or did some charge come from that side

58:36 I take it that the earn-out is still on our balance sheet, so there was no, let's say, charge from that side. It was really just the remaining transactions from the 10 needle business, which had a slightly negative impact still in the first half here. But the 2 million earn-out is still on our balance sheet. And as you said, in the second half, we have to take about the same amount of loss in this other segment on EBIT level.

59:09 That's fair to assume. I said a low single digit million amount. So if you think about the range of the first half year, you're not completely wrong. And then maybe again regarding to this earn out for from the Needles business that's in long term non current receivables booked. But I thought that they should that should be paid in 2027. So why is it in long term?

59:39 Yeah, it's a good question. Typically, you have a little bit of time after, let's say, this business year ends to first announce the numbers, whatever is relevant for that earn out. Let's assume it's something like sales and then you have a time to check that and you, so really when you have to pay it, So you see now from the calculation that this still takes a little bit more time until we really receive the cash. But for you important, the cash would then come in the next business year, 2027, 2028. And the fact that it is still on our balance sheet tells you that yes, we expect that that earn out to come.

1:00:26 And sorry, I believe we are at time, but we'll give you perhaps, Ed, another few minutes to ask your question. Ed, would you like to unmute your mic and ask a question? Perfect. Can you hear me? Yes, loud and clear, Ed, please. Thank you very much. My first question would just be on today's guidance and maybe looking at next year. the midpoint implies sort of roughly 80 million of incremental delivery systems revenue was around 100 million last year I was just curious sort of maybe appreciate high level and it's still early days of how we should expect that incremental revenue for next year and then sort of my second question would just be on life cycle management and again qualitatively here could you provide a flavour of some customers that either bringing new molecules or new markers to the market versus maybe existing IV formulations.

1:01:25 I mean, is this a niche or is there actually something that's quite a meaningful part of your business? And then finally, just sort of how you guys expect the cost of medical grade plastics to evolve over time. Well, I assume resin costs have been impacted this year, but just to refresh our memories on how that is potentially pass through to customers. Thanks.

1:01:50 So you are right if you take the midpoint of our annual guidance you end up with incremental roughly 18 million more and yes in the business year before it was roughly 100 million. Now going forward. Think of it when Simon mentioned that we are more or less linear growing. You have that CAGR of 15 in mind. And that tells you that the incremental revenue the next year will be slightly higher because you start from a higher basis when you grow with that rate. That's the way of thinking of this incremental revenue growth.

1:02:37 On the life cycle and the molecule side, I'm personally aware of five cases out of the 30 where we have a move from IV to sub-Q. I'm not sure what we can explain more. Can we give you some more flavour on the therapeutic areas? Existing and new therapeutic areas, I think it's fair to assume. Yes, I think you mentioned a few. Neurology, very exciting. Autoimmune disease. We see also some in oncology and infectious disease. I think those are very exciting. New therapy areas and existing therapy areas where we keep winning new clinical projects.

1:03:15 And out of the 30 projects that we won, roughly 50% are new, I think slightly more about 50%, 16-17 projects are new molecules and in two new therapeutic areas in the space of neurology, for instance. So it's basically broadening. So the IV sub-Q is one trend, but obviously many formulation teams are trying to go directly into sub-Q nowadays. And the third question on your medical grade and food grade or even industrial grade level as we see it. I mentioned before it is a program that runs all in all roughly three years. First of all, we have to test the respective plastics if they deliver the same results in our plastic molding tools.

1:04:08 Number one. And then number two, we have to negotiate with the respective sources to get their dual source situation. We have to test again, verify again. and then we have to convince and we do it in parallel our clients to actually move. So I would say so until so we so my wish is to go end of decade as I mentioned 29 ish 100 of our clients but there might be some stubborn ones which we don't want because the effort for instance in a situation where we have a drug or a device which comes end of life cycle it doesn't really make sense to push them for the last three four years but Generally, we try to move them all and this will give us a couple of EBIT percent points that we are going to share, 3-4% that we are going to share with our clients and these EBIT percentages will then counteract or counter work with the potential lower pricing towards the end of the decade in order to land at the clearly above 30% EBIT margin level.

1:05:13 I'm not sure if this helps. It's very clear. Thanks very much guys. Great. Thank you Ed. Thank you very much everyone for your interest and you continue to trust in Ipsomed and with that we'll close the call. Thank you. Thank you.

Follow Ypsomed Holding AG into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Simon Michel

CEO

Samuel Künzli

CFO

John Nunn

Analyst, Barclays

More from Ypsomed Holding AG